The company continues to drive global expansion by investing in high growth segments and expanding its innovation pipeline to new markets.
As CVD rates rise, so does the demand for devices that improve heart function and blood flow.
The union of the two companies creates a market opportunity of nearly $30 billion.
The company’s Bakken Research Centre in the Netherlands is centrally located for technology development and collaboration with physicians.
Using subcutaneous leads, rather than leads threaded through blood vessels to the heart, the EMBLEM Subcutaneous Implantable Defibrillator model is 19 percent slimmer and projected to last 40 percent longer than the original S-ICD, according to the company.